Loading organizations...
DeuterOncology NV is a Liege, Belgium-based biotechnology company that develops next-generation cancer therapies utilizing advanced deuteration technology to significantly enhance pharmacological drug properties. The organization's lead clinical candidate, DO-2, is a highly selective, brain-penetrant MET kinase and RAS pathway inhibitor specifically designed for the targeted treatment of lung cancer and other MET-driven malignancies. Operating as a venture-backed enterprise, the firm acquired the exclusive worldwide development and commercialization rights to this primary therapeutic asset from OCTIMET Oncology NV, which had originally licensed the underlying compound from Janssen Pharmaceutica in 2017. To support its ongoing pre-clinical validation and broader clinical development efforts, the business successfully completed a €5.65 million Series A financing round backed by lead investor Newton alongside several other institutional venture participants. DeuterOncology was officially founded in September 2020 by chief executive officer Dr. Timothy Perera.
DeuterOncology has raised $6.1M across 1 funding round.
DeuterOncology has raised $6.1M in total across 1 funding round.
DeuterOncology has raised $6.1M across 1 funding round. Most recently, it raised $6.1M Series A in January 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 19, 2023 | $6.1M Series A | Investsud, Newton Biocapital, Noshaq | — | Announced |
DeuterOncology has raised $6.1M in total across 1 funding round.
DeuterOncology's investors include InvestSud, Newton Biocapital, Noshaq.
